ArticleDrug testing and analysis2025
Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography-Tandem Mass Spectrometry and Structure-Activity Relationship Analysis.
Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Determination of Nitrosamine Drug Substance-Related Impurities Derived from Nortriptyline and Sertraline Using LC-MS/MS: A Comparative Evaluation of Chromatographic Separation and Pharmaceutical Application.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography-Tandem Mass Spectrometry and Structure-Activity Relationship Analysis.Drug testing and analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The presence of nitrosamines in numerous human medicinal products (HMP) has recently emerged as a cause for concern. Following the initial discovery of carcinogenic low molecular weight nitrosamines such as nitrosodimethylamine (NDMA) in HMP, regulatory authorities worldwide requested marketing authorization holders to perform risk assessments for the presence of nitrosamines in their products. The initially observed contaminations-mainly low molecular weight nitrosamines-were generated by organic solvent impurities or by-products from synthesis and nitrite carried over to finished products (FP). More recently, complex nitrosamine drug substance-related impurities (NDSRIs) have been reported arising from direct nitrosation of active pharmaceutical ingredients (APIs) at secondary amine groups in the presence of nitrite derived from excipients. In addition, an alternative route of API nitrosation is conceivable due to interaction with gastric acid and physiological nitrite after drug intake. Within this study, 13 secondary amine bearing APIs were selected to individually identify susceptibilities for nitrosation by using high physiological limit values in terms of pH and nitrite. Therefore, artificial gastric media were fortified with 200 μM sodium nitrite and increasing concentrations of APIs at pH 3.15 and 37°C for 2 h. All NDSRI concentrations were quantitatively determined via validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. Additionally, time-dependent nitrosations of selected APIs were monitored to kinetically assess the proportion of NDSRIs after the gastric passage. All results and observations were further processed by means of structure activity relationship (SAR) predictions to identify highly susceptible compounds in the group of concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.